Related Experiment Video
Updated: Jun 24, 2026
08:37
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
CD4 T-cell differentiation and inflammatory bowel disease.
Lauren A Zenewicz1, Andrey Antov, Richard A Flavell
1Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Trends in Molecular Medicine
|April 14, 2009
Summary
Naïve T cells differentiate into subsets like Th1, Th2, Th17, and regulatory T cells, crucial for immunity. Aberrant responses, particularly from Th17 cells, are implicated in inflammatory bowel disease (IBD), with new therapies emerging.
Area of Science:
- Immunology
- Cell Biology
Background:
- T-cell differentiation generates subsets (Th1, Th2, Th17, iTreg) with distinct immune functions.
- These subsets are vital for host defense against pathogens and cancer.
- Dysregulated T-cell responses are linked to chronic inflammatory diseases like inflammatory bowel disease (IBD).
Purpose of the Study:
- To highlight the role of T-cell subsets, especially Th17 cells, in the pathogenesis of IBD.
- To review the significance of Th17 cells in IBD.
- To discuss the therapeutic potential of targeting aberrant T-cell responses in IBD.
Main Methods:
- Review of recent immunological studies focusing on T-cell differentiation and function.
- Analysis of cytokine profiles and signaling pathways involved in T-cell subset generation.
- Examination of the role of specific T-cell subsets in IBD models and patient data.
Main Results:
- T-cell differentiation is regulated by distinct signaling pathways, producing specialized subsets.
- Th17 cells play a significant role in the inflammatory processes underlying IBD.
- Aberrant activity of T-cell subsets, particularly Th17, contributes to IBD pathology.
Conclusions:
- Understanding T-cell subset differentiation is key to comprehending immune responses.
- Th17 cells are a critical target for novel IBD therapies.
- Emerging therapeutics targeting aberrant Th responses show promise for treating IBD and related inflammatory conditions.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...